Philippines

Philippines

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
8.24 (7.20 - 9.36) 2019 Modelled IHME
8.3 (7.24 - 9.43) 2018 Modelled IHME
8.45 (7.38 - 9.62) 2017 Modelled IHME
8.98 (7.87 - 10.20) 2016 Modelled IHME
9.55 (8.41 - 10.83) 2015 Modelled IHME
9.77 (8.59 - 11.09) 2014 Modelled IHME
9.93 (8.73 - 11.27) 2013 Modelled IHME
10.05 (8.82 - 11.41) 2012 Modelled IHME
10.17 (8.91 - 11.56) 2011 Modelled IHME
10.32 (9.02 - 11.74) 2010 Modelled IHME
10.5 (9.17 - 11.96) 2009 Modelled IHME
10.7 (9.33 - 12.19) 2008 Modelled IHME
10.9 (9.49 - 12.43) 2007 Modelled IHME
11.11 (9.65 - 12.68) 2006 Modelled IHME
11.32 (9.81 - 12.92) 2005 Modelled IHME
11.54 (9.97 - 13.17) 2004 Modelled IHME
11.75 (10.14 - 13.42) 2003 Modelled IHME
11.97 (10.32 - 13.70) 2002 Modelled IHME
12.19 (10.54 - 13.93) 2001 Modelled IHME
12.4 (10.73 - 14.21) 2000 Modelled IHME
12.62 (10.94 - 14.48) 1999 Modelled IHME
12.83 (11.10 - 14.75) 1998 Modelled IHME
13.04 (11.28 - 15) 1997 Modelled IHME
13.24 (11.48 - 15.26) 1996 Modelled IHME
13.42 (11.64 - 15.48) 1995 Modelled IHME
13.58 (11.75 - 15.67) 1994 Modelled IHME
13.73 (11.88 - 15.87) 1993 Modelled IHME
13.87 (12.01 - 16.05) 1992 Modelled IHME
13.99 (12.11 - 16.22) 1991 Modelled IHME
14.1 (12.15 - 16.32) 1990 Modelled IHME
3.64 (2.94 - 4.50) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
1.16 (0.95 - 1.42) 2019 Modelled IHME
1.21 (0.99 - 1.47) 2018 Modelled IHME
1.32 (1.08 - 1.61) 2017 Modelled IHME
2.83 (2.33 - 3.44) 2016 Modelled IHME
4.27 (3.50 - 5.18) 2015 Modelled IHME
4.04 (3.32 - 4.91) 2014 Modelled IHME
3.51 (2.88 - 4.27) 2013 Modelled IHME
2.87 (2.36 - 3.49) 2012 Modelled IHME
2.33 (1.92 - 2.84) 2011 Modelled IHME
2.11 (1.73 - 2.57) 2010 Modelled IHME
2.16 (1.77 - 2.63) 2009 Modelled IHME
2.3 (1.88 - 2.80) 2008 Modelled IHME
2.5 (2.04 - 3.04) 2007 Modelled IHME
2.73 (2.23 - 3.34) 2006 Modelled IHME
2.98 (2.44 - 3.65) 2005 Modelled IHME
3.37 (2.76 - 4.11) 2004 Modelled IHME
3.93 (3.22 - 4.78) 2003 Modelled IHME
4.52 (3.71 - 5.49) 2002 Modelled IHME
4.98 (4.08 - 6.05) 2001 Modelled IHME
5.17 (4.23 - 6.28) 2000 Modelled IHME
5.17 (4.23 - 6.28) 1999 Modelled IHME
5.16 (4.23 - 6.27) 1998 Modelled IHME
5.16 (4.23 - 6.26) 1997 Modelled IHME
5.15 (4.23 - 6.25) 1996 Modelled IHME
5.15 (4.23 - 6.25) 1995 Modelled IHME
5.35 (4.39 - 6.49) 1994 Modelled IHME
5.91 (4.85 - 7.15) 1993 Modelled IHME
6.73 (5.53 - 8.14) 1992 Modelled IHME
7.73 (6.34 - 9.38) 1991 Modelled IHME
8.82 (7.24 - 10.69) 1990 Modelled IHME
0.7 2018 Survey/reported WHO WPRO, Woodring J et al, 2017
1.07 (0.76 - 1.44) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
45 (40 - 50) 2019 Modelled IHME
45 (40 - 50) 2018 Modelled IHME
45 (40 - 50) 2017 Modelled IHME
45 (40 - 50) 2016 Modelled IHME
45 (41 - 50) 2015 Modelled IHME
46 (41 - 50) 2014 Modelled IHME
46 (42 - 51) 2013 Modelled IHME
46 (42 - 51) 2012 Modelled IHME
47 (43 - 52) 2011 Modelled IHME
47 (43 - 52) 2010 Modelled IHME
47 (43 - 52) 2009 Modelled IHME
48 (43 - 52) 2008 Modelled IHME
48 (43 - 53) 2007 Modelled IHME
48 (44 - 53) 2006 Modelled IHME
48 (44 - 53) 2005 Modelled IHME
49 (44 - 53) 2004 Modelled IHME
49 (45 - 54) 2003 Modelled IHME
50 (45 - 54) 2002 Modelled IHME
50 (46 - 54) 2001 Modelled IHME
50 (46 - 55) 2000 Modelled IHME
50 (46 - 55) 1999 Modelled IHME
50 (46 - 55) 1998 Modelled IHME
50 (46 - 55) 1997 Modelled IHME
50 (46 - 55) 1996 Modelled IHME
50 (46 - 55) 1995 Modelled IHME
50 (46 - 55) 1994 Modelled IHME
50 (46 - 55) 1993 Modelled IHME
50 (46 - 55) 1992 Modelled IHME
50 (46 - 55) 1991 Modelled IHME
50 (46 - 55) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
50 2018 Survey/reported WHO/UNICEF
55 2017 Survey/reported WHO/UNICEF
59 2016 Survey/reported WHO/UNICEF
56 2015 Survey/reported WHO/UNICEF
51 2014 Survey/reported WHO/UNICEF
46 2013 Survey/reported WHO/UNICEF
39 2012 Survey/reported WHO/UNICEF
46 2011 Survey/reported WHO/UNICEF
37 2010 Survey/reported WHO/UNICEF
34 2009 Survey/reported WHO/UNICEF
21 2008 Survey/reported WHO/UNICEF
9 2007 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
65 2018 Survey/reported WHO/UNICEF
72 2017 Survey/reported WHO/UNICEF
86 2016 Survey/reported WHO/UNICEF
60 2015 Survey/reported WHO/UNICEF
67 2014 Survey/reported WHO/UNICEF
89 2013 Survey/reported WHO/UNICEF
88 2012 Survey/reported WHO/UNICEF
87 2011 Survey/reported WHO/UNICEF
77 2010 Survey/reported WHO/UNICEF
85 2009 Survey/reported WHO/UNICEF
88 2008 Survey/reported WHO/UNICEF
87 2007 Survey/reported WHO/UNICEF
77 2006 Survey/reported WHO/UNICEF
49 2005 Survey/reported WHO/UNICEF
48 2004 Survey/reported WHO/UNICEF
52 2003 Survey/reported WHO/UNICEF
42 2002 Survey/reported WHO/UNICEF
45 2001 Survey/reported WHO/UNICEF
7 2000 Survey/reported WHO/UNICEF
32 1999 Survey/reported WHO/UNICEF
30 1998 Survey/reported WHO/UNICEF
31 1997 Survey/reported WHO/UNICEF
35 1996 Survey/reported WHO/UNICEF
38 1995 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2015 Survey/reported HIV And AIDS Data Hub for Asia-Pacific, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2006
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
No
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.01 (0.80 - 1.26) 2019 Modelled IHME
1.01 (0.81 - 1.26) 2018 Modelled IHME
1.01 (0.81 - 1.26) 2017 Modelled IHME
1.01 (0.80 - 1.25) 2016 Modelled IHME
1 (0.80 - 1.25) 2015 Modelled IHME
1.01 (0.80 - 1.25) 2014 Modelled IHME
1.02 (0.81 - 1.26) 2013 Modelled IHME
1.03 (0.82 - 1.28) 2012 Modelled IHME
1.04 (0.83 - 1.30) 2011 Modelled IHME
1.06 (0.84 - 1.32) 2010 Modelled IHME
1.07 (0.85 - 1.34) 2009 Modelled IHME
1.09 (0.86 - 1.35) 2008 Modelled IHME
1.1 (0.88 - 1.37) 2007 Modelled IHME
1.12 (0.89 - 1.39) 2006 Modelled IHME
1.12 (0.89 - 1.39) 2005 Modelled IHME
1.11 (0.88 - 1.38) 2004 Modelled IHME
1.1 (0.87 - 1.36) 2003 Modelled IHME
1.07 (0.85 - 1.33) 2002 Modelled IHME
1.05 (0.83 - 1.30) 2001 Modelled IHME
1.03 (0.82 - 1.27) 2000 Modelled IHME
1.01 (0.80 - 1.25) 1999 Modelled IHME
0.99 (0.78 - 1.23) 1998 Modelled IHME
0.97 (0.77 - 1.20) 1997 Modelled IHME
0.95 (0.76 - 1.19) 1996 Modelled IHME
0.95 (0.75 - 1.18) 1995 Modelled IHME
0.95 (0.75 - 1.18) 1994 Modelled IHME
0.95 (0.75 - 1.19) 1993 Modelled IHME
0.96 (0.76 - 1.20) 1992 Modelled IHME
0.97 (0.77 - 1.22) 1991 Modelled IHME
0.99 (0.78 - 1.25) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.9 (0.30 - 2) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
35.2 (15.90 - 54.50) 2011 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
20 (17 - 24) 2019 Modelled IHME
20 (17 - 24) 2018 Modelled IHME
20 (17 - 24) 2017 Modelled IHME
20 (17 - 24) 2016 Modelled IHME
20 (18 - 23) 2015 Modelled IHME
20 (17 - 23) 2014 Modelled IHME
20 (17 - 23) 2013 Modelled IHME
20 (17 - 23) 2012 Modelled IHME
20 (17 - 23) 2011 Modelled IHME
20 (17 - 22) 2010 Modelled IHME
20 (17 - 22) 2009 Modelled IHME
19 (17 - 22) 2008 Modelled IHME
19 (16 - 22) 2007 Modelled IHME
19 (16 - 22) 2006 Modelled IHME
19 (16 - 22) 2005 Modelled IHME
19 (16 - 22) 2004 Modelled IHME
19 (16 - 21) 2003 Modelled IHME
18 (16 - 21) 2002 Modelled IHME
18 (16 - 21) 2001 Modelled IHME
18 (16 - 21) 2000 Modelled IHME
18 (15 - 21) 1999 Modelled IHME
18 (16 - 21) 1998 Modelled IHME
18 (16 - 21) 1997 Modelled IHME
18 (16 - 21) 1996 Modelled IHME
18 (16 - 21) 1995 Modelled IHME
18 (16 - 21) 1994 Modelled IHME
18 (16 - 21) 1993 Modelled IHME
18 (16 - 21) 1992 Modelled IHME
18 (16 - 21) 1991 Modelled IHME
18 (16 - 21) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2015 Survey/reported HIV And AIDS Data Hub for Asia-Pacific, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2006
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
No
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
8.24 (%)
2019
(7.2 - 9.36(%))
IHME
HCV (RNA/cAg+)
1.01 (%)
2019
(0.8 - 1.26(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
6,057
2019
(4,764 - 7,660)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
5,110
2019
(4,061 - 6,445)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.70 (%)
2018, survey/surveillance
WHO WPRO, Woodring J et al, 2017

Prevalence PWID

HCV
35.20 (%)
2011, latest modelled
(15.90 - 54.50(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
50 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2015
(0 - 0)
HIV And AIDS Data Hub for Asia-Pacific, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines